Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- 3From Dread to Certainty: Individual Accounts of Strengthening
- 4Trial of pro-Palestine activist begins
- 5Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Instructions to Expand Your Advantages from an Open Record Reward
- SUVs Known for Their Looks As opposed to Their Capacity
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Manual for Famous Beverages 2024
- Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- Germany unveils rescue plan for struggling chemical sector
- German Cabinet advances bill to cut greenhouse emissions from fuels
